Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1186/s12885-016-2474-z http://hdl.handle.net/11449/178149 |
Resumo: | Background: The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom BCG (Bacillus Calmette-Guerin) has failed or is contraindicated are recently increasing due to the development of new drugs. Although agents like mitomycin C and BCG are routinely used, there is a need for more potent and/or less-toxic agents. In this scenario, a new perspective is represented by P-MAPA (Protein Aggregate Magnesium-Ammonium Phospholinoleate-Palmitoleate Anhydride), developed by Farmabrasilis (non-profit research network). This study detailed and characterized the mechanisms of action of P-MAPA based on activation of mediators of Toll-like Receptors (TLRs) 2 and 4 signaling pathways and p53 in regulating angiogenesis and apoptosis in an animal model of NMIBC, as well as, compared these mechanisms with BCG treatment. Results: Our results demonstrated the activation of the immune system by BCG (MyD88-dependent pathway) resulted in increased inflammatory cytokines. However, P-MAPA intravesical immunotherapy led to distinct activation of TLRs 2 and 4-mediated innate immune system, resulting in increased interferons signaling pathway (TRIF-dependent pathway), which was more effective in the NMIBC treatment. Interferon signaling pathway activation induced by P-MAPA led to increase of iNOS protein levels, resulting in apoptosis and histopathological recovery. Additionally, P-MAPA immunotherapy increased wild-type p53 protein levels. The increased wild-type p53 protein levels were fundamental to NO-induced apoptosis and the up-regulation of BAX. Furthermore, interferon signaling pathway induction and increased p53 protein levels by P-MAPA led to important antitumor effects, not only suppressing abnormal cell proliferation, but also by preventing continuous expansion of tumor mass through suppression of angiogenesis, which was characterized by decreased VEGF and increased endostatin protein levels. Conclusions: Thus, P-MAPA immunotherapy could be considered an important therapeutic strategy for NMIBC, as well as, opens a new perspective for treatment of patients that are refractory or resistant to BCG intravesical therapy. |
id |
UNSP_5818b43b87f0ea0858258f85b4370dac |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/178149 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifierAngiogenesisBacillus Calmette-GuerinBladder CancerImmunotherapyP-MAPAP53Toll-like ReceptorBackground: The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom BCG (Bacillus Calmette-Guerin) has failed or is contraindicated are recently increasing due to the development of new drugs. Although agents like mitomycin C and BCG are routinely used, there is a need for more potent and/or less-toxic agents. In this scenario, a new perspective is represented by P-MAPA (Protein Aggregate Magnesium-Ammonium Phospholinoleate-Palmitoleate Anhydride), developed by Farmabrasilis (non-profit research network). This study detailed and characterized the mechanisms of action of P-MAPA based on activation of mediators of Toll-like Receptors (TLRs) 2 and 4 signaling pathways and p53 in regulating angiogenesis and apoptosis in an animal model of NMIBC, as well as, compared these mechanisms with BCG treatment. Results: Our results demonstrated the activation of the immune system by BCG (MyD88-dependent pathway) resulted in increased inflammatory cytokines. However, P-MAPA intravesical immunotherapy led to distinct activation of TLRs 2 and 4-mediated innate immune system, resulting in increased interferons signaling pathway (TRIF-dependent pathway), which was more effective in the NMIBC treatment. Interferon signaling pathway activation induced by P-MAPA led to increase of iNOS protein levels, resulting in apoptosis and histopathological recovery. Additionally, P-MAPA immunotherapy increased wild-type p53 protein levels. The increased wild-type p53 protein levels were fundamental to NO-induced apoptosis and the up-regulation of BAX. Furthermore, interferon signaling pathway induction and increased p53 protein levels by P-MAPA led to important antitumor effects, not only suppressing abnormal cell proliferation, but also by preventing continuous expansion of tumor mass through suppression of angiogenesis, which was characterized by decreased VEGF and increased endostatin protein levels. Conclusions: Thus, P-MAPA immunotherapy could be considered an important therapeutic strategy for NMIBC, as well as, opens a new perspective for treatment of patients that are refractory or resistant to BCG intravesical therapy.University of Campinas (UNICAMP) Laboratory of Urogenital Carcinogenesis and Immunotherapy Department of Structural and Functional Biology, P.O. BOX 6109North of Parana State University (UENP) Institute of BiologyUNESP - Univ Estadual Paulista Department of Anatomy Institute of BiosciencesFarmabrasilis R and D DivisionUniversity of Campinas (UNICAMP) NanoBioss Institute of ChemistryUniversity of Campinas (UNICAMP) Department of Internal MedicineSão Paulo State University (UNESP) Department of Physical EducationUniversity of Ljubljana Institute of Cell Biology Faculty of MedicineUNESP - Univ Estadual Paulista Department of Anatomy Institute of BiosciencesSão Paulo State University (UNESP) Department of Physical EducationUniversidade Estadual de Campinas (UNICAMP)Institute of BiologyUniversidade Estadual Paulista (Unesp)Farmabrasilis R and D DivisionFaculty of MedicineGarcia, Patrick ViannaSeiva, Fábio Rodrigues FerreiraCarniato, Amanda Pocolde Mello Júnior, Wilson [UNESP]Duran, NelsonMacedo, Alda Mariade Oliveira, Alexandre Gabarra [UNESP]Romih, RokNunes, Iseu da SilvaNunes, Odilon da SilvaFávaro, Wagner José2018-12-11T17:28:59Z2018-12-11T17:28:59Z2016-07-07info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://dx.doi.org/10.1186/s12885-016-2474-zBMC Cancer, v. 16, n. 1, 2016.1471-2407http://hdl.handle.net/11449/17814910.1186/s12885-016-2474-z2-s2.0-849783787552-s2.0-84978378755.pdfScopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengBMC Cancer1,464info:eu-repo/semantics/openAccess2023-11-12T06:16:05Zoai:repositorio.unesp.br:11449/178149Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T17:31:13.315471Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier |
title |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier |
spellingShingle |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier Garcia, Patrick Vianna Angiogenesis Bacillus Calmette-Guerin Bladder Cancer Immunotherapy P-MAPA P53 Toll-like Receptor |
title_short |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier |
title_full |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier |
title_fullStr |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier |
title_full_unstemmed |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier |
title_sort |
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier |
author |
Garcia, Patrick Vianna |
author_facet |
Garcia, Patrick Vianna Seiva, Fábio Rodrigues Ferreira Carniato, Amanda Pocol de Mello Júnior, Wilson [UNESP] Duran, Nelson Macedo, Alda Maria de Oliveira, Alexandre Gabarra [UNESP] Romih, Rok Nunes, Iseu da Silva Nunes, Odilon da Silva Fávaro, Wagner José |
author_role |
author |
author2 |
Seiva, Fábio Rodrigues Ferreira Carniato, Amanda Pocol de Mello Júnior, Wilson [UNESP] Duran, Nelson Macedo, Alda Maria de Oliveira, Alexandre Gabarra [UNESP] Romih, Rok Nunes, Iseu da Silva Nunes, Odilon da Silva Fávaro, Wagner José |
author2_role |
author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual de Campinas (UNICAMP) Institute of Biology Universidade Estadual Paulista (Unesp) Farmabrasilis R and D Division Faculty of Medicine |
dc.contributor.author.fl_str_mv |
Garcia, Patrick Vianna Seiva, Fábio Rodrigues Ferreira Carniato, Amanda Pocol de Mello Júnior, Wilson [UNESP] Duran, Nelson Macedo, Alda Maria de Oliveira, Alexandre Gabarra [UNESP] Romih, Rok Nunes, Iseu da Silva Nunes, Odilon da Silva Fávaro, Wagner José |
dc.subject.por.fl_str_mv |
Angiogenesis Bacillus Calmette-Guerin Bladder Cancer Immunotherapy P-MAPA P53 Toll-like Receptor |
topic |
Angiogenesis Bacillus Calmette-Guerin Bladder Cancer Immunotherapy P-MAPA P53 Toll-like Receptor |
description |
Background: The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom BCG (Bacillus Calmette-Guerin) has failed or is contraindicated are recently increasing due to the development of new drugs. Although agents like mitomycin C and BCG are routinely used, there is a need for more potent and/or less-toxic agents. In this scenario, a new perspective is represented by P-MAPA (Protein Aggregate Magnesium-Ammonium Phospholinoleate-Palmitoleate Anhydride), developed by Farmabrasilis (non-profit research network). This study detailed and characterized the mechanisms of action of P-MAPA based on activation of mediators of Toll-like Receptors (TLRs) 2 and 4 signaling pathways and p53 in regulating angiogenesis and apoptosis in an animal model of NMIBC, as well as, compared these mechanisms with BCG treatment. Results: Our results demonstrated the activation of the immune system by BCG (MyD88-dependent pathway) resulted in increased inflammatory cytokines. However, P-MAPA intravesical immunotherapy led to distinct activation of TLRs 2 and 4-mediated innate immune system, resulting in increased interferons signaling pathway (TRIF-dependent pathway), which was more effective in the NMIBC treatment. Interferon signaling pathway activation induced by P-MAPA led to increase of iNOS protein levels, resulting in apoptosis and histopathological recovery. Additionally, P-MAPA immunotherapy increased wild-type p53 protein levels. The increased wild-type p53 protein levels were fundamental to NO-induced apoptosis and the up-regulation of BAX. Furthermore, interferon signaling pathway induction and increased p53 protein levels by P-MAPA led to important antitumor effects, not only suppressing abnormal cell proliferation, but also by preventing continuous expansion of tumor mass through suppression of angiogenesis, which was characterized by decreased VEGF and increased endostatin protein levels. Conclusions: Thus, P-MAPA immunotherapy could be considered an important therapeutic strategy for NMIBC, as well as, opens a new perspective for treatment of patients that are refractory or resistant to BCG intravesical therapy. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-07-07 2018-12-11T17:28:59Z 2018-12-11T17:28:59Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1186/s12885-016-2474-z BMC Cancer, v. 16, n. 1, 2016. 1471-2407 http://hdl.handle.net/11449/178149 10.1186/s12885-016-2474-z 2-s2.0-84978378755 2-s2.0-84978378755.pdf |
url |
http://dx.doi.org/10.1186/s12885-016-2474-z http://hdl.handle.net/11449/178149 |
identifier_str_mv |
BMC Cancer, v. 16, n. 1, 2016. 1471-2407 10.1186/s12885-016-2474-z 2-s2.0-84978378755 2-s2.0-84978378755.pdf |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
BMC Cancer 1,464 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128821730213888 |